CYP2C9 substrates Aprepitant

Although not assessed, this marked leduetion in aprepitant levels could result in reduced eflieaey. In the UK, the manufacturer recommends that concurrent use of aprepitant and strong indueers of CYP3A4, such as rifampicin, be avoided. They also name phenytoin (see also Aprepitant + CYP2C9 substrates , above), carbamazepine, and phenobarbital, and... 

Aprepitant may be affected by paroxetine, CYP2C9 substrates (eg, phenytoin, tolbutamide, warfarin), CYP3A4 substrates (eg, alprazolam, cisapride, dexamethasone, docetaxel, etoposide, ifosfamide, imatinib, irinotecan, methylprednisolone, midazolam, paclitaxel, pimozide, triazolam, vinblastine, vincristine, vinorelbine), and oral contraceptives. 

Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9. Use aprepitant with caution in patients receiving concomitant medicinal products, including chemotherapy agents that are primarily metabolized through CYP3A4 (docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine). 

Aprepitant is a substrate for CYP3A4 and an inducer of CYP2C9 and 3A4 (it also has moderate, dose-dependent CYP3A4 inhibitory properties),... 

---